BioSpace News Archive

DisposeRx Inc. (http://www.disposerx.com) celebrated a turning point in the opioid crisis today by joining President Trump at the White House as he signed into law a comprehensive legislative package designed to stem the nation’s opioid crisis.

Today, the American Association of Nurse Practitioners (AANP) released the following statement after President Trump signed a comprehensive package of anti-opioid bills into law with a key provision enabling the NP workforce to continue to expand access to Medication Assisted Treatments (MATs) for opioid-addicted patients nationwide:

PurpleStride Supports the Pancreatic Cancer Action Network’s Urgent Mission to Save Lives, Double Survival by 2020

In the first of its kind research, OCHIN, combined with its collaborative partners, have published a study that piloted the capture and integration of data on social determinants of health (SDH)— the conditions of an individual’s environment that impact their health and quality of life – into the electronic health record (EHR).

Sweeping bipartisan package encourages treatment and recovery efforts; company believes more work is needed and recommends next steps

Amgen (NASDAQ: AMGN) today announced that it is making Repatha® (evolocumab), an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, available at a reduced list price of $5,850 per year.

The home diagnostics market will grow at a healthy 3.5% value CAGR, surpassing US$ 6.3 million by 2026.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2018 and reviewed recent progress with its approved and investigational medicines.

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that it will assume full development and commercial responsibility for its collaboration with Galapagos (Euronext: GLPG) to discover and develop new therapies to treat cystic fibrosis (CF).

The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock on October 24, 2018.